Lateral Flow Assays (LFA) Market Size & Share, by Product (Kits & Reagents, Readers & Scanners, Accessories); Application; Technology; Test Type; Sample Type; End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Lateral Flow Assays Market - Regional Analysis

North America Market Insights

The North America lateral flow assays (LFA) market is dominating and is expected to hold the regional revenue share of 38.6% by 2035. The market is driven by the advanced healthcare infrastructure, high healthcare expenditure, and strong regulatory frameworks from the FDA and Health Canada. A primary trend is the strategic integration of rapid diagnostics into value-based care and decentralized testing models supported by reimbursement pathways from the CMS. Moreover, the government spending focuses on public health preparedness with agencies such as BARDA funding next-gen assays for pandemic response and biological threats. The shift toward managing chronic diseases at the point of care and the expansion of retail clinics and home testing further propel the demand. Besides, the collaborative initiatives between public health bodies and manufacturers ensure a pipeline for advanced tests, sustaining the region's leadership through a combination of procurement stability and continuous product evolution.

The U.S. market continues to expand and is driven by the high clinical burden of infectious and parasitic diseases and the integration of rapid testing into routine care. According to the CDC December 2024 data, physician offices recorded 10.2 million visits with these conditions as the primary diagnostics including 790,000 admissions resulting in hospitalization. This sustained patient volume creates a consistent demand for rapid diagnostic tools at the point of care and in emergency settings. Regulatory authorization of lateral flow-based OTC products further supports the market growth. The FDA authorized Abbott Diagnostics in February 2025, BinaxNOW COVID-19 Antigen Self-Test and BinaxNOW Ag Card, both lateral flow assays designed for visual read and decentralized testing. These approvals enabled large-scale deployment beyond hospitals into homes, pharmacies, and public screening programs. Collectively, these data indicate an active market growth in the U.S.

FDA Authorized Molecular Diagnostic Tests

Source: FDA January 2026

The ongoing highly pathogenic avian influenza outbreaks in Canada are strengthening the demand for rapid field-deployable diagnostic solutions, directly supporting the growth of the market. According to the Government of Canada, January 2025, the Canadian Food Inspection Agency has managed widespread outbreaks that resulted in significant economic impact, including 32.3% decline in chicken exports and an 8.7% decline in turkey exports in 2022 compared to 2021, highlighting the urgency for faster disease containment. While current diagnostics rely on centralized rRT PCR testing at CFIA laboratories, result turnaround times exceed 4 hours, and logistical delays limit real-time decision-making at farms. As a result, the CFIA and federal partners are identifying the need for a rapid, affordable lateral flow-based test capable of detecting influenza A, including H5 and H7 subtypes, at sensitivity levels comparable to molecular assays. Hence, the market in Canada has strategic growth, and the demand is expected to accelerate the adoption of advanced LFAs in veterinary surveillance, outbreak response, and biosecurity programs.

APAC Market Insights

The Asia Pacific lateral flow assays market is the fastest-growing and is poised to grow at a CAGR of 7.7% by 2035. The market is driven by the vast population bases, increasing healthcare expenditure, and strong governmental focus on expanding diagnostic access in primary and rural care settings. The key drivers include the rising prevalence of infectious and chronic diseases, substantial public health investments in pandemic preparedness, and a growing local manufacturing ecosystem aiming for self-sufficiency. A significant trend is the health initiatives which prioritize the domestic production of medical devices including the rapid tests. Further, the regulatory harmonization efforts, such as those by the Asia Pacific Medical Technology Association, aim to streamline market access, while digital health integration is enhancing the utility of point-of-care testing in decentralized healthcare models across the region.

The China lateral flow assays (LFA) market growth is closely linked to the persistent and rising incidence of notifiable infectious diseases reported nationwide. According to the NLM January 2025 study, official surveillance data show that the reported Class A and B infectious disease cases increased from 2.43 million in 2022 to 3.51 million in 2023, while the incidence rate rose from 172.2 to 248.8 per 100,00 population, indicating renewed pressure on disease monitoring systems. Further, the high-volume diseases such as viral hepatitis, pulmonary tuberculosis, syphilis, and gonorrhea consistently accounted for over 92% reported cases between 2018 and 2023, creating a sustained demand for frequent screening and early detection tools in hospitals and public health clinics. The adoption of lateral flow assays across China’s public health and primary care systems is contributing to steady market growth alongside regulatory support from national health authorities.

Incidence and Mortality of Class A and B Public Infectious Diseases in China

Source: NLM January 2025

The lateral flow assays (LFA) market in India is growing steadily and is supported by the high infectious disease burden, expanding public healthcare expenditure, and the government-led screening programs. According to the IIJMR data in February 2024, India recorded 4 billion outpatient visits annually across public health facilities, creating a sustained demand for rapid point-of-care diagnostics in primary and community settings. Further, the national health mission finances large-scale screening programs for tuberculosis, HIV, malaria, and viral hepatitis, with diagnostics representing a core expenditure line item. Moreover, the IBEF April 2023 data shows that the health expenditure increased to 2.1% of GDP by 2023, reflecting a rising allocation toward preventive care and disease surveillance. Collectively, high patient volumes, expanding publicly funded screening initiatives, and regulatory support for rapid diagnostics underpin the sustained growth of the lateral flow assays market across India’s public health system and decentralized care environments.

Europe Market Insights

The Europe lateral flow assays market is defined by the stringent regulatory oversight under the in vitro diagnostic regulation and a strong push toward integrated decentralized healthcare models. The primary driver is the strategic EU level initative to strengthen the health system resilience that promotes the stockpiling of critical medical countermeasures, including rapid diagnostics. Aging demographics and the rising burden of antimicrobial-resistant infections are increasing the clinical demand for point-of-care testing across community and hospital settings. The market is transitioning toward higher value quantitative and digitally connected assays, moving beyond simple qualitative strips. Further, the market is experiencing a stable environment focused demand on preparedness rather than reactive purchasing.

The UK market is growing steadily and is supported by the sustained government spending on diagnostics, infectious disease surveillance, and emergency preparedness. According to the Government of the UK, April 2022 data, the government invested over 5.9 billion euros in testing and diagnostics primarily to maintain national infectious disease monitoring and rapid response capacity. Further, the NLM study in March 2025 depicts that 80 million PCR and lateral flow assay device tests were reported, with ongoing procurement to support outbreak readiness and seasonal respiratory surveillance. Moreover, the Office for National Statistics data in May 2024 shows that the UK healthcare expenditure exceeded £292 billion in 2023, with diagnostics and laboratory services embedded within NHS preventive and community care budgets. Overall UK experiences a steady demand for lateral flow assays across hospitals, community healthcare settings, and public health programs in the UK.

The lateral flow assays (LFA) market in Germany is supported by the sustained public healthcare expenditure, statutory health insurance reimbursement, and government-led infectious disease surveillance. According to the Debatis April 2023 data, Germany’s total health expenditure exceeded €501 billion in 2023, representing 12.0% of GDP, with diagnostics funded under the statutory health insurance system. Moreover, the EU Health Preparedness July 2023 report shows multiple antigen tests have been evaluated to meet the criteria and definitions by the Health Security Committee. Additionally, the Infection Protection Act continues to mandate the testing and surveillance measures for notifiable infectious diseases, sustaining government procurement and reimbursement of rapid diagnostic tests beyond the pandemic period. These data reinforce Germany’s position as a stable growth market within Europe.

COVID-19 Antigen Tests in Germany

Source: EU Health Preparedness July 2023